NLSP 6-K: merger conditions completed; delisting date announcement

Rhea-AI Filing Summary

NLS Pharmaceutics (NLSP) furnished a 6-K noting a press release announcing completion of material conditions precedent for its merger and a delisting date for Kadimastem’s shares.

Issued on October 28, 2025, the notice indicates merger milestones have been satisfied and that Kadimastem’s shares have a delisting date announced. Full details are contained in Exhibit 99.1, titled “NLS Pharmaceutics and Kadimastem Announce Completion of Material Conditions Precedent for Merger Transaction and Delisting Date of Kadimastem’s Shares.”

Insights

Cross-border M&A analyst

Procedural merger milestone; progress signaled via press release.

The company reports that “material conditions precedent” to the merger have been completed, a common step before closing. The announcement also states a delisting date for Kadimastem’s shares, indicating preparations for post-transaction listing changes.

As disclosed, specifics of the conditions and timing are contained in Exhibit 99.1. Actual impact depends on final closing mechanics and any remaining approvals or processes described in the press release.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the Month of October 2025 (Report No. 5)

Commission File Number: 001-39957

NLS PHARMACEUTICS LTD.

(Translation of registrant’s name into English)

The Circle 6

8058 Zurich, Switzerland

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

☒ Form 20-F ☐ Form 40-F

CONTENTS

On October 28, 2025, NLS Pharmaceutics Ltd. issued a press release titled: “NLS Pharmaceutics and Kadimastem Announce Completion of Material Conditions Precedent for Merger Transaction and Delisting Date of Kadimastem’s Shares.” A copy of this press release is furnished herewith as Exhibit 99.1.

EXHIBIT INDEX

Exhibit Number		Description of Document
99.1		Press release titled: “NLS Pharmaceutics and Kadimastem Announce Completion of Material Conditions Precedent for Merger Transaction and Delisting Date of Kadimastem’s Shares”

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	NLS Pharmaceutics Ltd.
Date: October 28, 2025	By:	/s/ Alexander C. Zwyer
		Name:	Alexander C. Zwyer
		Title:	Chief Executive Officer

2

FAQ

What did NLS Pharmaceutics (NLSP) disclose in this 6-K?

It furnished a press release stating completion of material conditions precedent for its merger and announcing a delisting date for Kadimastem’s shares (Exhibit 99.1).

When was the NLSP press release furnished?

On October 28, 2025, as part of the 6-K filing.

Where can I find the detailed merger and delisting information for NLSP?

See Exhibit 99.1: “NLS Pharmaceutics and Kadimastem Announce Completion of Material Conditions Precedent for Merger Transaction and Delisting Date of Kadimastem’s Shares.”

Who signed the NLSP 6-K?

Chief Executive Officer Alexander C. Zwyer signed the report.

Does NLSP file annual reports on Form 20-F or Form 40-F?

The company indicates it files annual reports under cover of Form 20-F.